Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent the most common
subtype of NETs. The incidence of all NETs, and specifically GEP NETs, has risen …
subtype of NETs. The incidence of all NETs, and specifically GEP NETs, has risen …
The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors
JM Cloyd, B Konda, MH Shah… - Expert Review of Clinical …, 2019 - Taylor & Francis
Introduction: Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are unique and
complex neoplasms, exhibiting a wide spectrum of diverse clinical behaviors. The …
complex neoplasms, exhibiting a wide spectrum of diverse clinical behaviors. The …
[HTML][HTML] Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization …
JX Xu, DH Wu, LW Ying, HG Hu - World Journal of …, 2021 - ncbi.nlm.nih.gov
Abstract According to the 2019 World Health Organization (WHO) classification, well-
differentiated grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are …
differentiated grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are …
177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
S Das, T Al-Toubah, G El-Haddad… - Expert review of …, 2019 - Taylor & Francis
ABSTRACT Introduction: 177Lutetium-[DOTA°, Tyr3] octreotate (177Lu-DOTATATE) is a
type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 …
type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 …
[HTML][HTML] Combination systemic therapies in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A comprehensive review of …
Simple Summary This comprehensive review explores evolving systemic combination
regimens for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors …
regimens for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors …
Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 …
TPS514 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which
represent approximately 70% of NETs, frequently develop metastatic disease with limited …
represent approximately 70% of NETs, frequently develop metastatic disease with limited …
Role of immunotherapy in gastro‐enteropancreatic neuroendocrine neoplasms (gep‐nens): Current advances and future directions
L Fang, D Arvind, A Dowlati… - Journal of …, 2021 - Wiley Online Library
Neuroendocrine neoplasms (NENs) are heterogeneous tumours originating from
neuroendocrine cells (Pearse & Polak, Gut, 1971, 12,783). They were once considered as …
neuroendocrine cells (Pearse & Polak, Gut, 1971, 12,783). They were once considered as …
Medical management of gastroenteropancreatic neuroendocrine tumors: current strategies and future advances
A Mohamed, JR Strosberg - Journal of nuclear medicine, 2019 - Soc Nuclear Med
Gastroenteropancreatic neuroendocrine tumors are relatively rare neoplasms, characterized
by a propensity to secrete hormones that cause distinct clinical syndromes. During the past …
by a propensity to secrete hormones that cause distinct clinical syndromes. During the past …
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of: 177: Lu-DOTATATE peptide receptor …
A Kalshetty, A Ramaswamy, V Ostwal… - Nuclear medicine …, 2018 - journals.lww.com
Materials and methods A total of 46 patients with refractory or progressive symptomatic GEP-
NETs (previously treated at various stages with long-acting octreotide, chemotherapy …
NETs (previously treated at various stages with long-acting octreotide, chemotherapy …
Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
M Kesavan, PG Claringbold, JH Turner - Neuroendocrinology, 2014 - karger.com
Background: The combination of radiopeptide therapy [peptide receptor radionuclide
therapy (PRRT)] with radiosensitizing chemotherapy of gastroenteropancreatic …
therapy (PRRT)] with radiosensitizing chemotherapy of gastroenteropancreatic …